A Multinational, Randomized, Double-Blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-Stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.

Trial Profile

A Multinational, Randomized, Double-Blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-Stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Ombrabulin (Primary) ; Cisplatin
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Jan 2013 Status changed from active, no longer recruiting to discontinued, according to a Sanofi media release.
    • 08 Jan 2013 Primary endpoint 'Progression-free-survival' has been met, according to a Sanofi media release.
    • 19 Dec 2012 Planned number of patients changed from 350 to 355 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top